Loading
companiesCompany
Shanghai Allist Pharmaceuticals
Allist is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR pill, partnered with ArriVent for the rest of the world.
Also called: Allist艾力斯
Overview
Shanghai Allist Pharmaceuticals, based in Shanghai, founded in 2004 and listed as 688578.SS, is the single-product lung cancer company behind furmonertinib, China's other third-generation EGFR tablet, partnered with ArriVent for the rest of the world. Furmonertinib, sold as Ivesa, was approved in 2021 and for first-line use in 2022 on the FURLONG trial, and its exon 20 insertion programme is licensed to ArriVent BioPharma in the United States with the global FURVENT phase 3. OnCo links it to furmonertinib and FURLONG. Its profitability on one drug shows the size of China's EGFR-mutant lung cancer market, and whether the exon 20 programme gives it a global product rather than a domestic one is the open question. Furmonertinib has its own page.
Headquarters
Shanghai, CN
Scorecard
All companies#191of 1244 companies, score 31
- approved products +6
- phase 3 +3
- targets +4
- modalities +2
- regions +1
- registry trials +15
1 approved, 1 in phase 3, 0 earlier, 2 targets, 59 registry studies. Formula on the scorecards page.
Type
Biotech · 688578.SS
Stage
Public
Website
Founded
2004
ApprovedSmall-molecule third-generation EGFR TKI
Furmonertinib · Ivesa
Furmonertinib is a Chinese lung cancer pill of the same class as osimertinib, which more than doubled the time before cancer grew compared with gefitinib in the FURLONG trial.
Phase 3small molecule
Sitneprotafib is an experimental small-molecule drug from Allist Pharmaceuticals in phase 3 trials for non-small-cell lung cancer, colorectal cancer and pancreatic ductal adenocarcinoma, with its target not yet stated publicly.
Similar pages
- TrialAENEAS
Shares FURLONG and the tag china.
- TreatmentGlecirasib
Shares JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation, A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation., A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China, JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation.
- CancerKRAS G12C-mutant non-small-cell lung cancer
Shares JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation, A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China, A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1, Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation.
- TechnologyKRAS & RAS inhibitors
Shares A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation., A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China, JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation, A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1.
fronts
drugs
ApprovedSmall-molecule third-generation EGFR TKI
Furmonertinib · Ivesa
Phase 3small molecule
trials
A Phase II Study Evaluating JAB-21822 Monotherapy in Adult Patients With Pancreatic Cancer and Other Solid Tumors Harboring the KRAS p.G12C Mutation.A Study Evaluating Furmonertinib Plus Platinum-based Doublet Chemotherapy Versus Osimertinib in Patients With Epidermal Growth Factor Receptor (EGFR) Sensitizing Mutation-Positive Non-squamous Non-Small Cell Lung Cancer (NSCLC) and Brain MetastasesA Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in ChinaA Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1Efficacy and Safety of Furmonertinib in Patients With Locally Advanced or Metastatic NSCLC With EGFR Exon 20 InsertionFirmonertinib Versus Platinum Based Chemotherapy as First-line Treatment for NSCLC With EGFR PACC or EGFR l861q MutationFURLONGFurmonertinib Monotherapy and Combination Therapy in Advanced EGFR Mutant NSCLC With Uncleared ctDNAJAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C MutationJAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C MutationPhase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C MutationTo Assess the Efficacy and Safety of Furmonertinib Versus Placebo, in Patients With Epidermal Growth Factor Receptor Mutation Positive Stage II-IIIA Non-small Cell Lung Carcinoma, Following Complete Tumour Resection With or Without Adjuvant Chemotherapy